Trading in Novo Nordisk shares by board members, executives and associated persons on 11 August 2017
Bagsværd, Denmark, 14 August 2017
- This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.
Further information
Media: | ||
Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
Investors : | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com |
Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
Christina Jensen | +45 3079 3009 | cnje@novonordisk.com |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Company announcement No 63 / 2017
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
Upcoming Life Sciences Events
- April 2024
- Basel: Swiss Biotech Day 2024
- London: BioTrinity 2024
- Singapore: Asia Bio Partnering Forum
Latest company news
There are currently no news available for this portal